Aspira Pathlab P/E Ratio
Current P/E Ratio
40.77
High Valuation
Very High - High growth expectations or significantly overvalued
Aspira Pathlab (ASPIRA) P/E ratio is 40.77 (High), EPS (TTM) ₹1.97, current price ₹115.00 on BSE — Very High - High growth expectations or significantly overvalued. Also explore ASPIRA price trends to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
40.77
Current Price
₹115.00
EPS (TTM)
₹1.97
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
95.64
Sector Median
41.54
Sector Rank
#11 of 57
Sector Percentile
19.3%
Earnings Breakdown (TTM)
TTM EPS
₹1.54
Mar 2025
₹0.66
Jun 2025
₹0.41
ASPIRA P/E Ratio — Valuation Signal & Historical Context
Aspira Pathlab P/E 40.77 — signal: Overvalued.
- Stock appears overvalued with PE of 40.77, suggesting caution for new investments
- Trading at discount to sector average PE of 95.64
ASPIRA vs Healthcare Services Peers — P/E Ratio Comparison
Aspira Pathlab P/E 40.77 vs Healthcare Services average 95.64, median 41.54 — range 7.19–1587.86.
Sector Average
95.64
Sector Median
41.54
Lowest P/E
7.19
Highest P/E
1587.86
Companies
57
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Star Imaging And Path Lab | STARIMAGIN | 7.19 | ₹135 | Low |
| Abate AS Industries | ABATEAS | 11.13 | ₹134 | Low |
| Deccan Health Care | DECCAN | 12.09 | ₹31 | Low |
| Nidan Labs & Healthcare | NIDAN | 12.27 | ₹19 | Low |
| One Global Service Provi… | ONEGLOBAL | 14.36 | ₹1,056 | Low |
| Shanmuga Hospital | SHANMUGA | 15.88 | ₹67 | Moderate |
| Invicta Diagnostic | INVICTA | 17.27 | ₹82 | Moderate |
| Indraprastha Medical Cor… | INDRAMEDCO | 17.55 | ₹3,254 | Moderate |
| Krsnaa Diagnostics | KRSNAA | 18.39 | ₹1,757 | Moderate |
| Chandan Healthcare | CHANDAN | 18.55 | ₹500 | Moderate |